Paige Vinson

Paige Vinson

Auto-generated profile, based on publicly available information

Paige Vinson

High-Throughput Screening Center, Southern Research, Birmingham, Alabama

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2012 in Molecular Pharmacology
Verified
Journal Article
Open access
PDF file
KGKaren J Gregory
Karen J Gregory
MNMeredith J. Noetzel
Meredith J. Noetzel
JRJerri M. Rook
Jerri M. Rook
PVPaige N. Vinson
Paige N. Vinson
SSShaun Stauffer
Shaun Stauffer
PCP. Jeffrey Conn
P. Jeffrey Conn
Drug discovery programs increasingly are focusing on allosteric modulators as a means to modify the activity of G protein-coupled receptor (GPCR) targets. Allosteric binding sites are topographically distinct from the endogenous ligand (orthosteric) binding site, which allows for co-occupation of a single receptor with the endogenous ligand and an allosteric modulator that can alter receptor pharmacological characteristics. Negative allosteric modulators (NAMs) inhibit and positive allosteric modulators (PAMs) enhance the affinity and/or efficacy of orthosteric agonists. Established approaches for estimation of affinity and efficacy values for orthosteric ligands are not appropriate for allosteric modulators, and this presents challenges for fully understanding the actions of novel modulators of GPCRs. Metabotropic glutamate receptor 5 (mGlu5) is a family C GPCR for which a large array of allosteric modulators have been identified. We took advantage of the many tools for probing allosteric sites on mGlu5 to validate an operational model of allosterism that allows quantitative estimation of modulator affinity and cooperativity values. Affinity estimates derived from functional assays fit well with affinities measured in radioligand binding experiments for both PAMs and NAMs with diverse chemical scaffolds and varying degrees of cooperativity. We observed modulation bias for PAMs when we compared mGlu5-mediated Ca2+ mobilization and extracellular signal-regulated kinase 1/2 phosphorylation data. Furthermore, we used this model to quantify the effects of mutations that reduce binding or potentiation by PAMs. This model can be applied to PAM and NAM potency curves in combination with maximal fold-shift data to derive reliable estimates of modulator affinities.

1 May 2020 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
GAGeetika Aggarwal
Geetika Aggarwal
JZJonah E. Zarrow
Jonah E. Zarrow
ZMZahra Mashhadi
Zahra Mashhadi
CFC. Robb Flynn
C. Robb Flynn
PVPaige Vinson
Paige Vinson
SDSean S. Davies
Sean S. Davies
N-acyl-phosphatidylethanolamine phospholipase D (NAPE-PLD) (EC 3.1.4.4) catalyzes the final step in the biosynthesis of N-acyl-ethanolamides (NAEs). Reduced NAPE-PLD expression and activity may contribute to obesity and inflammation, but a lack of effective NAPE-PLD inhibitors has been a major obstacle to elucidating the role of NAPE-PLD and NAE biosynthesis in these processes. The endogenous bile acid lithocholic acid (LCA) inhibits NAPE-PLD activity (with an IC50 68 μM), but LCA is also a highly potent ligand for TGR5 (EC50 0.52 μM). Recently, the first selective small-molecule inhibitor of NAPE-PLD, ARN19874, has been reported (having an IC50 34 µM). To identify more potent inhibitors of NAPE-PLD, here we used a quenched fluorescent NAPE analog, PED-A1, as a substrate for recombinant mouse NAPE-PLD to screen a panel of bile acids and a library of experimental compounds (the “Spectrum Collection”). Muricholic acids and several other bile acids inhibited NAPE-PLD with potency similar to LCA. We identified 14 potent NAPE-PLD inhibitors were identified in the Spectrum Collection, with the two most potent (IC50 ~2 μM) being symmetrically substituted dichlorophenes, i.e. hexachlorophene and bithionol. Structure-activity relationship assays using additional substituted dichlorophenes identified key moieties needed for NAPE-PLD inhibition. Both hexachlorophene and bithionol exhibited significant selectivity for NAPE-PLD compared to non-target lipase activities such as Streptomyces chromofuscus PLD or serum lipase. Both also effectively inhibited NAPE-PLD activity in cultured HEK293 cells. We conclude that symmetrically substituted dichlorophenes potently inhibit NAPE-PLD in cultured cells and have significant selectivity for NAPE-PLD versus other tissue-associated lipases.

2 November 2023 in SLAS Discovery
Verified
Journal Article
Open access
YMYohanka Martinez-Gzegozewska
Yohanka Martinez-Gzegozewska
LRLynn Rasmussen
Lynn Rasmussen
SMSara McKellip
Sara McKellip
AMAnna Manuvakhova
Anna Manuvakhova
NNN. Miranda Nebane
N. Miranda Nebane
PVPaige Vinson
Paige Vinson
A rapid drug discovery response to influenza outbreaks with the potential to reach pandemic status could help minimize the virus's impact by reducing the time to identify anti-influenza drugs. Although several anti-influenza strategies have been considered in the search for new drugs, only a few therapeutic agents are approved for clinical use. The cytopathic effect induced by the influenza virus in Madin Darby canine kidney (MDCK) cells has been widely used for high-throughput anti-influenza drug screening, but the fact that the MDCK cells are not human cells constitutes a disadvantage when searching for new therapeutic agents for human use. We have developed a highly sensitive cell-based imaging assay for the identification of inhibitors of influenza A and B virus that is high-throughput compatible using the A549 human cell line. The assay has also been optimized for the assessment of the neutralizing effect of anti-influenza antibodies in the absence of trypsin, which allows testing of purified antibodies and serum samples. This assay platform can be applied to full high-throughput screening campaigns or later stages requiring quantitative potency determinations for structure-activity relationships.

16 August 2022 in Science Signaling
Verified
Journal Article
Closed access
DCDerrick Cumberbatch
Derrick Cumberbatch
TMTetsuya Mori
Tetsuya Mori
JYJie Yang
Jie Yang
DMDehui Mi
Dehui Mi
PVPaige Vinson
Paige Vinson
CJCarl Hirschie Johnson
Carl Hirschie Johnson
The intrinsic fluorescence of samples confounds the use of fluorescence-based sensors. This is of particular concern in high-throughput screening (HTS) applications using large chemical libraries containing intrinsically fluorescent compounds. To overcome this problem, we developed a bioluminescence resonance energy transfer (BRET) Ca 2+ sensor, CalfluxCTN. We demonstrated that it reliably reported changes in intracellular Ca 2+ concentrations evoked by an agonist and an antagonist of the human muscarinic acetylcholine receptor M 1 (hM 1 R) even in the presence of the fluorescent compound fluorescein, which interfered with a standard fluorescent HTS sensor (Fluo-8). In an HTS using a chemical library containing fluorescent compounds, CalfluxCTN accurately identified agonists and antagonists that were missed or miscategorized using Fluo-8. Moreover, we showed that a luciferase substrate that becomes activated only when inside cells generated long-lasting BRET signals in HTS, enabling results to be reliably compared among replicate samples for hours. Thus, the use of a self-luminescent sensor instead of a fluorescent sensor could facilitate the complete screening of chemical libraries in a high-throughput context and enable analysis of autofluorescent samples in many different applications.

16 May 2024 in SLAS Discovery
Verified
Journal Article
Open access
LRLynn Rasmussen
Lynn Rasmussen
SSShalisa Sanders
Shalisa Sanders
MSMelinda Sosa
Melinda Sosa
SMSara McKellip
Sara McKellip
NNN. Miranda Nebane
N. Miranda Nebane
PVPaige N. Vinson
Paige N. Vinson
Four years after the beginning of the COVID-19 pandemic, it is important to reflect on the events that have occurred during that time and the knowledge that has been gained. The response to the pandemic was rapid and highly resourced; it was also built upon a foundation of decades of federally funded basic and applied research. Laboratories in government, pharmaceutical, academic, and non-profit institutions all played roles in advancing pre-2020 discoveries to produce clinical treatments. This perspective provides a summary of how the development of high-throughput screening methods in a biosafety level 3 (BSL-3) environment at Southern Research Institute (SR) contributed to pandemic response efforts. The challenges encountered are described, including those of a technical nature as well as those of working under the pressures of an unpredictable virus and pandemic.

Verified
Journal Article
Open access
PDF file
WLWentao Lyu
Wentao Lyu
DMDehui Mi
Dehui Mi
PVPaige N. Vinson
Paige N. Vinson
Yingping XiaoYingping Xiao
Yingping Xiao
Guolong ZhangGuolong Zhang
Guolong Zhang
The rapid emergence of antibiotic resistance demands new antimicrobial strategies that are less likely to develop resistance. Augmenting the synthesis of endogenous host defense peptides (HDPs) has been proven to be an effective host-directed therapeutic approach. This study aimed to identify small-molecule compounds with a strong ability to induce endogenous HDP synthesis for further development as novel antimicrobial agents. By employing a stable HDP promoter-driven luciferase reporter cell line known as HTC/AvBD9-luc, we performed high-throughput screening of 5002 natural and synthetic compounds and identified 110 hits with a minimum Z-score of 2.0. Although they were structurally and functionally diverse, half of these hits were inhibitors of class I histone deacetylases, the phosphoinositide 3-kinase pathway, ion channels, and dopamine and serotonin receptors. Further validations revealed mocetinostat, a benzamide histone deacetylase inhibitor, to be highly potent in enhancing the expression of multiple HDP genes in chicken macrophage cell lines and jejunal explants. Importantly, mocetinostat was more efficient than entinostat and tucidinostat, two structural analogs, in promoting HDP gene expression and the antibacterial activity of chicken macrophages. Taken together, mocetinostat, with its ability to enhance HDP synthesis and the antibacterial activity of host cells, could be potentially developed as a novel antimicrobial for disease control and prevention.